Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Gellert Balazs Karvaly"'
Publikováno v:
Pharmaceutics, Vol 16, Iss 6, p 792 (2024)
The philosophy, practice, and clinical impact of therapeutic drug monitoring (TDM) has changed profoundly with the appearance of widely available and, in a technical sense, commonly applicable modeling, simulation, and dosing software tools in the pa
Externí odkaz:
https://doaj.org/article/85f7bca524004d5cace6cb61041acc3f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Eszter Gulyás, István László Horváth, Marie Anne Engh, Stefania Bunduc, Fanni Dembrovszky, Péter Fehérvári, András Bánvölgyi, Dezső Csupor, Péter Hegyi, Gellért Balázs Karvaly
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract An estimated 70% of critically ill patients receive antibiotics, most frequently beta-lactams. The pharmacokinetic properties of these substances in this patient population are poorly predictable. Therapeutic drug monitoring (TDM) is helpful
Externí odkaz:
https://doaj.org/article/a243f151a19042a395da6c407f4899a0
Autor:
Adrienne Fehér, István Vincze, James Rudge, Gyula Domján, Barna Vásárhelyi, Gellért Balázs Karvaly
Publikováno v:
Diagnostics, Vol 14, Iss 17, p 1939 (2024)
Our aim was to compare the performance of complementary clinical laboratory approaches to monitoring exposure to apixaban and rivaroxaban, the most prescribed direct-acting oral anticoagulants (DOAC’s): an automated commercial anti-Xa chromogenic a
Externí odkaz:
https://doaj.org/article/68ddb8fe47c24536bc8770c6dcb0af6f
Autor:
Gellért Balázs Karvaly, István Vincze, Michael Noel Neely, István Zátroch, Zsuzsanna Nagy, Ibolya Kocsis, Csaba Kopitkó
Publikováno v:
Pharmaceutics, Vol 16, Iss 3, p 358 (2024)
Population pharmacokinetic (pop-PK) models constructed for model-informed precision dosing often have limited utility due to the low number of patients recruited. To augment such models, an approach is presented for generating fully artificial quasi-
Externí odkaz:
https://doaj.org/article/66c127ee5e374e399f14cccabc4dec79
Autor:
Bálint András Barta, Mihály Ruppert, Klemens Erwin Fröhlich, Miguel Cosenza-Contreras, Attila Oláh, Alex Ali Sayour, Krisztián Kovács, Gellért Balázs Karvaly, Martin Biniossek, Béla Merkely, Oliver Schilling, Tamás Radovits
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-15 (2021)
Abstract Background Reduced cardiovascular risk in premenopausal women has been the focus of research in recent decades. Previous hypothesis-driven experiments have highlighted the role of sex hormones on distinct inflammatory responses, mitochondria
Externí odkaz:
https://doaj.org/article/30edd34d01414922b1fd4b084cf37cf7
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 239 (2023)
Orally administered, small-molecule anticancer drugs with tumor-specific cellular protein targets (OACD) have revolutionized oncological pharmacotherapy. Nevertheless, the differences in exposure to these drugs in the systemic circulation and extrava
Externí odkaz:
https://doaj.org/article/1da3c3902d214d33b2ace8c1b8cacccd
Autor:
Gellért Balázs Karvaly, István Karádi, István Vincze, Michael N. Neely, Eszter Trojnár, Zoltán Prohászka, Éva Imreh, Barna Vásárhelyi, András Zsáry
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract The inadequate adherence of patients whose hyperlipidemia is treated with atorvastatin (ATR) to medical instructions presents a serious health risk. Our aim was to develop a flexible approach based on therapeutic drug monitoring (TDM), nonpa
Externí odkaz:
https://doaj.org/article/e3277a6d16c34a73b9a26ecfca0b40fd
Autor:
Gellért Balázs Karvaly, István Vincze, Alexandra Balogh, Zoltán Köllő, Csaba Bödör, Barna Vásárhelyi
Publikováno v:
Molecules, Vol 27, Iss 15, p 4766 (2022)
Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precis
Externí odkaz:
https://doaj.org/article/8edf52f11d1b4781ad1e50d2ef73d53b
Autor:
Gellért Balázs Karvaly, Michael N Neely, Krisztián Kovács, István Vincze, Barna Vásárhelyi, Roger W Jelliffe
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229873 (2020)
BACKGROUND:The clinical value of therapeutic drug monitoring can be increased most significantly by integrating assay results into clinical pharmacokinetic models for optimal dosing. The correct weighting in the modeling process is 1/variance, theref
Externí odkaz:
https://doaj.org/article/7f4aaddd49b54733b0e768b176d7c5a7